Professional Summary
Specializing In
Practice Locations
Patient Ratings
Referring Physicians
Biography
Kavitha Ramchandran MD, graduated with an undergraduate degree in Human Biology from Stanford University, did medical school and residency training in medicine at University of California, San Francisco and completed her fellowship in Medical Oncology and Palliative Medicine at Northwestern University, Chicago. She joined faculty at Stanford University in 2010. Currently she is a Clinical Associate Professor of Medicine in the Division of Oncology. She serves as the Medical Director of Cancer Care Services for the Stanford Cancer Center across the enterprise, and is the inaugural Chief of Mentoring and Career Development for the Division of Oncology.
Dr. Ramchandran is recognized for her contributions as a leader in the research of thoracic malignancies with a specific focus in thymic epithelial tumors. She serves as a principal investigator and sub-investigator on several research trials from early phase to phase II and phase III studies. The goal of these trials is developing novel approaches and identifying new targets for the treatment of both thoracic malignancies as well as rare tumors such as thymic epithelial tumors including thymoma and thymic cancers.
Dr. Ramchandran also has research focuses on developing care delivery models that incorporate values (patients, family members, and clinicians), as well as novel means of palliative care education. She does research on online education and in patient reported outcomes (PROs). She also is part of an active thoracic oncology trials group recruiting patients for clinical trials using novel therapeutics.
Dr. Ramchandran is recognized for her contributions as a leader in the integration of palliative and oncology care. Dr. Ramchandran is one of a small number of dual trained faculty who are working to build synergies between the fields of oncology and palliative medicine in the areas of supportive care research, and novel models of care. In her care of patients Dr. Ramchandran values a deep relationship with the families she cares for. She provides care that is aligned with the patient and family's personal values with the goal of the best quality of life and longevity possible.
Dr. Ramchandran is recognized for her contributions as a leader in the research of thoracic malignancies with a specific focus in thymic epithelial tumors. She serves as a principal investigator and sub-investigator on several research trials from early phase to phase II and phase III studies. The goal of these trials is developing novel approaches and identifying new targets for the treatment of both thoracic malignancies as well as rare tumors such as thymic epithelial tumors including thymoma and thymic cancers.
Dr. Ramchandran also has research focuses on developing care delivery models that incorporate values (patients, family members, and clinicians), as well as novel means of palliative care education. She does research on online education and in patient reported outcomes (PROs). She also is part of an active thoracic oncology trials group recruiting patients for clinical trials using novel therapeutics.
Dr. Ramchandran is recognized for her contributions as a leader in the integration of palliative and oncology care. Dr. Ramchandran is one of a small number of dual trained faculty who are working to build synergies between the fields of oncology and palliative medicine in the areas of supportive care research, and novel models of care. In her care of patients Dr. Ramchandran values a deep relationship with the families she cares for. She provides care that is aligned with the patient and family's personal values with the goal of the best quality of life and longevity possible.
View Full Biography
Professional Summary
Education & Certifications
- Residency: UCSF Dept of Internal Medicine (2007) CA
- Fellowship: Northwestern University Hematology and Oncology Fellowship (2009) IL
- Board Certification: American Board of Internal Medicine, Hospice and Palliative Medicine (2012)
- Board Certification: American Board of Internal Medicine, Medical Oncology (2010)
- Medical Education: University of California at San Francisco School of Medicine (2004) CA
- Board Certification, Oncology, Oncology (2009)
Honors & Awards
- Honoree, AACR/ASCO: Methods in Clinical Cancer Research (2009)
- Honoree, Clinical Effectiveness Leadership Training- CELT (2014)
- Nominee, Medical Residency Teaching Award (2012)
Memberships
- Associate Chief of Mentoring and Career Development, Division of Oncology, School of Medicine (2021 - Present)
- Geriatric Oncology Panel, National Comprehensive Cancer Network (2021 - Present)
- Fellow, Center for Global Health, Stanford University (2020 - Present)
- Palliative Care Panel, National Comprehensive Cancer Network (2020 - Present)
- Medical Director, Cancer Care Services, Stanford Cancer Center (2019 - Present)
- Faculy, Global Oncology- GO (2015 - Present)
- Palliative Care Best Practices Committee, National Comprehensive Cancer Network (2014 - Present)
- Patient and Survivor Care Committee, American Society of Clinical Oncology (2014 - Present)
- Faculty, Global Resource to Advance Cancer Education (2012 - Present)
- Board member, Cancer Awareness, Research and Education, San Francisco General Hospital (2002 - Present)
Administrative Appointments
- Medical Director, Cancer Care Services, Stanford Cancer Center (2019 - Present)
Publications
-
My Friend, My Patient
Ramchandran, K. (2009). My Friend, My Patient. JOURNAL OF PALLIATIVE MEDICINE, 12(1), 95–96. -
Sex Differences in Susceptibility to Carcinogens
Ramchandran, K., & Patel, J. D. (2009). Sex Differences in Susceptibility to Carcinogens. SEMINARS IN ONCOLOGY, 36(6), 516–523. -
Phantom Limb Pain #212
Ramchandran, K., & Hauser, J. (2010). Phantom Limb Pain #212. JOURNAL OF PALLIATIVE MEDICINE, 13(10), 1285–1286. -
Emerging Concepts in the Pathology and Molecular Biology of Advanced Non-Small Cell Lung Cancer
Kulesza, P., Ramchandran, K., & Patel, J. D. (2011). Emerging Concepts in the Pathology and Molecular Biology of Advanced Non-Small Cell Lung Cancer. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 136(2), 228–238. -
A predictive model to identify hospitalized cancer patients at risk for 30-day mortality based on admission criteria via the electronic medical record.
Ramchandran, K. J., Shega, J. W., von Roenn, J., Schumacher, M., Szmuilowicz, E., Rademaker, A., … Weitzman, S. (2013). A predictive model to identify hospitalized cancer patients at risk for 30-day mortality based on admission criteria via the electronic medical record. Cancer, 119(11), 2074–80. -
Palliative Care Always
Ramchandran, K., & Von Roenn, J. H. (2013). Palliative Care Always. ONCOLOGY-NEW YORK, 27(1), 13-? -
Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era.
Riess, J. W., Nagpal, S., Iv, M., Zeineh, M., Gubens, M. A., Ramchandran, K., … Wakelee, H. A. (2014). Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era. Clinical Lung Cancer, 15(3), 202–6. -
Implementation of supportive care and best supportive care interventions in clinical trials enrolling patients with cancer†.
Lee, R. T., Ramchandran, K., Sanft, T., & Von Roenn, J. (2015). Implementation of supportive care and best supportive care interventions in clinical trials enrolling patients with cancer†. Annals of Oncology , 26(9), 1838–45. -
Integrating Palliative Care Into Oncology: A Way Forward
Ramchandran, K., Tribett, E., Dietrich, B., & Von Roenn, J. (2015). Integrating Palliative Care Into Oncology: A Way Forward. CANCER CONTROL, 22(4), 386–95. -
Integrated Palliative Care and Oncologic Care in Non-Small-Cell Lung Cancer.
Chandrasekar, D., Tribett, E., & Ramchandran, K. (2016). Integrated Palliative Care and Oncologic Care in Non-Small-Cell Lung Cancer. Current Treatment Options in Oncology, 17(5), 23-? -
The Current State of Palliative Care for Patients Cared for at Leading US Cancer Centers: The 2015 NCCN Palliative Care Survey.
Calton, B. A., Alvarez-Perez, A., Portman, D. G., Ramchandran, K. J., Sugalski, J., & Rabow, M. W. (2016). The Current State of Palliative Care for Patients Cared for at Leading US Cancer Centers: The 2015 NCCN Palliative Care Survey. Journal of the National Comprehensive Cancer Network , 14(7), 859–66. -
The Appropriate Provision of Primary Versus Specialist Palliative Care to Cancer Patients: Oncologists' Perspectives.
Gidwani, R., Nevedal, A., Patel, M., Blayney, D. W., Timko, C., Ramchandran, K., … Asch, S. M. (2016). The Appropriate Provision of Primary Versus Specialist Palliative Care to Cancer Patients: Oncologists' Perspectives. Journal of Palliative Medicine. -
The Appropriate Provision of Primary versus Specialist Palliative Care to Cancer Patients: Oncologists' Perspectives
Gidwani, R., Nevedal, A., Patel, M., Blayney, D. W., Timko, C., Ramchandran, K., … Asch, S. M. (2017). The Appropriate Provision of Primary versus Specialist Palliative Care to Cancer Patients: Oncologists' Perspectives. JOURNAL OF PALLIATIVE MEDICINE, 20(4), 395–403. -
Quality Of End-Of-Life Care Is Higher In The VA Compared To Care Paid For By Traditional Medicare
Gidwani-Marszowski, R., Needleman, J., Mor, V., Faricy-Anderson, K., Boothroyd, D. B., Hsin, G., … Asch, S. M. (2018). Quality Of End-Of-Life Care Is Higher In The VA Compared To Care Paid For By Traditional Medicare. HEALTH AFFAIRS, 37(1), 95–103. -
Oncologists' Views on Using Value to Guide Cancer Treatment Decisions
Gidwani-Marszowski, R., Nevedal, A. L., Blayney, D. W., Patel, M., Kelly, P. A., Timko, C., … Asch, S. M. (2018). Oncologists' Views on Using Value to Guide Cancer Treatment Decisions. VALUE IN HEALTH, 21(8), 931–37. -
Palliative care clinicians and online education in India: a survey.
Kiss-Lane, T., Spruijt, O., Day, T., Lam, V., Ramchandran, K. J., Chan, S., … Lorenz, K. A. (2018). Palliative care clinicians and online education in India: a survey. BMJ Supportive & Palliative Care. -
Automated Survival Prediction in Metastatic Cancer Patients Using High-Dimensional Electronic Medical Record Data.
Gensheimer, M. F., Henry, A. S., Wood, D. J., Hastie, T. J., Aggarwal, S., Dudley, S. A., … Chang, D. T. (2018). Automated Survival Prediction in Metastatic Cancer Patients Using High-Dimensional Electronic Medical Record Data. Journal of the National Cancer Institute. -
Feasibility of a massive online open course to teach skills in primary palliative care for a global audience.
Kerkar, A. P., DeNofrio, J., Tribett, E. L., & Ramchandran, K. (2018). Feasibility of a massive online open course to teach skills in primary palliative care for a global audience. JOURNAL OF CLINICAL ONCOLOGY, 36(34). -
Automated Survival Prediction in Metastatic Cancer Patients Using High-Dimensional Electronic Medical Record Data
Gensheimer, M. F., Henry, A. S., Wood, D. J., Hastie, T. J., Aggarwal, S., Dudley, S. A., … Chang, D. T. (2019). Automated Survival Prediction in Metastatic Cancer Patients Using High-Dimensional Electronic Medical Record Data. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 111(6), 568–74. -
Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.
Hellyer, J. A., Stehr, H., Das, M., Padda, S. K., Ramchandran, K., Neal, J. W., … Wakelee, H. A. (2019). Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands), 134, 42–45. -
Introducing Palliative Care within the Treatment of End-Stage Liver Disease: The Study Protocol of a Cluster Randomized Controlled Trial.
Verma, M., Kosinski, A. S., Volk, M. L., Taddei, T., Ramchandran, K., Bakitas, M., … Navarro, V. (2019). Introducing Palliative Care within the Treatment of End-Stage Liver Disease: The Study Protocol of a Cluster Randomized Controlled Trial. Journal of Palliative Medicine, 22(S1), 34–43. -
Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of non-small cell lung cancer patients.
Jeong, Y., Hellyer, J. A., Stehr, H., Hoang, N. T., Niu, X., Das, M., … Diehn, M. (2019). Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of non-small cell lung cancer patients. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies.
Hellyer, J. A., Gubens, M. A., Cunanan, K. M., Padda, S. K., Burns, M., Spittler, A. J., … Loehrer, P. J. (2019). Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies. Lung Cancer (Amsterdam, Netherlands), 137, 71–75. -
Health System and Beneficiary Costs Associated With Intensive End-of-Life Medical Services.
Gidwani-Marszowski, R., Asch, S. M., Mor, V., Wagner, T. H., Faricy-Anderson, K., Illarmo, S., … Needleman, J. (2019). Health System and Beneficiary Costs Associated With Intensive End-of-Life Medical Services. JAMA Network Open, 2(9), e1912161. -
ctDNA analysis for personalization of consolidation immunotherapy in localized non-small cell lung cancer.
Moding, E. J., Liu, Y., Nabet, B., Chabon, J. J., Chaudhuri, A., Hui, A. B., … Diehn, M. (2019). ctDNA analysis for personalization of consolidation immunotherapy in localized non-small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY, 37(15). -
Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC.
Chaft, J. E., Costa, D. B., Muzikansky, A., Shrager, J. B., Lanuti, M., Huang, J., … Neal, J. W. (2019). Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC. JOURNAL OF CLINICAL ONCOLOGY, 37(15). -
Symptom relief and palliative care in gynecologic oncology.
Roy, M., & Ramchandran, K. (2019). Symptom relief and palliative care in gynecologic oncology. Current Opinion in Obstetrics & Gynecology. -
Palliative care clinicians and online education in India: a survey
Kiss-Lane, T., Spruijt, O., Day, T., Lam, V., Ramchandran, K. J., Chan, S., … Lorenz, K. A. (2019). Palliative care clinicians and online education in India: a survey. BMJ SUPPORTIVE & PALLIATIVE CARE, 9(4). -
Feasibility and design of a cloud-based digital platform in patients with advanced cancer.
Roy, M., Hall, E. T., Velazquez, B., Shah, S., Fardeen, T., Cunanan, K., … Ramchandran, K. (2019). Feasibility and design of a cloud-based digital platform in patients with advanced cancer. JOURNAL OF CLINICAL ONCOLOGY, 37(27). -
The role of palliative care in the management of patients with lung cancer
Tan, I., & Ramchandran, K. (2020). The role of palliative care in the management of patients with lung cancer. LUNG CANCER MANAGEMENT. -
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.
Nabet, B. Y., Esfahani, M. S., Moding, E. J., Hamilton, E. G., Chabon, J. J., Rizvi, H., … Diehn, M. (2020). Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. Cell. -
KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer.
Binkley, M. S., Jeon, Y.-J., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D. S., … Diehn, M. (2020). KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
A mid-chemoradiation dynamic risk model integrating tumor features and ctDNA analysis for lung cancer outcome prediction.
Moding, E. J., Esfahani, M. S., Nabet, B., Liu, Y., Chabon, J. J., He, J., … Diehn, M. (2020). A mid-chemoradiation dynamic risk model integrating tumor features and ctDNA analysis for lung cancer outcome prediction. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Distress screening through PROMIS at an academic cancer center and network site: Implementation of a hybrid model.
Roy, M., Neal, J. W., Bugos, K., Sharp, C., Falconer, P., Rosenthal, E. L., … Ramchandran, K. (2020). Distress screening through PROMIS at an academic cancer center and network site: Implementation of a hybrid model. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition.
Binkley, M. S., Jeon, Y.-J. J., Nesselbush, M., Moding, E. J., Nabet, B. Y., Almanza, D., … Diehn, M. (2020). KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition. Cancer Discovery. -
DEVELOPMENT, FEASIBILITY AND ACCEPTABILITY OF AN ONLINE COURSE TO TEACH PRIMARY PALLIATIVE CARE SKILLS TO HEPATOLOGY PROVIDERS.
Verma, M., Denofrio, J., Ramchandran, K., Taddei, T. H., Volk, M., & Navarro, V. J. (2020). DEVELOPMENT, FEASIBILITY AND ACCEPTABILITY OF AN ONLINE COURSE TO TEACH PRIMARY PALLIATIVE CARE SKILLS TO HEPATOLOGY PROVIDERS. HEPATOLOGY, 72, 1156–57. -
End-of-Life Cost Trajectories in Cancer Patients Treated by Medicare versus the Veterans Health Administration.
Gidwani, R., Asch, S. M., Needleman, J., Faricy-Anderson, K., Boothroyd, D. B., Illarmo, S., … Wagner, T. H. (2020). End-of-Life Cost Trajectories in Cancer Patients Treated by Medicare versus the Veterans Health Administration. Journal of the American Geriatrics Society. -
Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
Zhang, M., Rodrigues, A. J., Pollom, E. L., Gibbs, I. C., Soltys, S. G., Hancock, S. L., … Li, G. (2021). Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases. Journal of Neuro-Oncology. -
End-of-Life Practice Patterns in Head and Neck Cancer.
Vukkadala, N., Fardeen, T., Ramchandran, K., & Divi, V. (2021). End-of-Life Practice Patterns in Head and Neck Cancer. The Laryngoscope. -
Brief Report: Role of Consolidation Durvalumab in patients with EGFR and HER2 Mutant Unresectable Stage III NSCLC.
Hellyer, J. A., Aredo, J. V., Das, M., Ramchandran, K., Padda, S. K., Neal, J. W., & Wakelee, H. A. (2021). Brief Report: Role of Consolidation Durvalumab in patients with EGFR and HER2 Mutant Unresectable Stage III NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer. -
How could we forget?
Ramchandran, K. (2021). How could we forget? The Lancet. Respiratory Medicine. -
A noninvasive approach for early prediction of therapeutic benefit from immune checkpoint inhibition for lung cancer
Nabet, B. Y., Esfahani, M. S., Hamilton, E. G., Chabon, J. J., Moding, E. J., Rizvi, H., … Diehn, M. (2020). A noninvasive approach for early prediction of therapeutic benefit from immune checkpoint inhibition for lung cancer. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Distress Screening Through Patient-Reported Outcomes Measurement Information System (PROMIS) at an Academic Cancer Center and Network Site: Implementation of a Hybrid Model.
Neal, J. W., Roy, M., Bugos, K., Sharp, C., Galatin, P. S., Falconer, P., … Ramchandran, K. (2021). Distress Screening Through Patient-Reported Outcomes Measurement Information System (PROMIS) at an Academic Cancer Center and Network Site: Implementation of a Hybrid Model. JCO Oncology Practice, OP2000473. -
Investigating gene expression profiles associated with clinical radiation resistance in KEAP1/NFE2L2 wildtype lung cancer.
Binkley, M. S., Jeon, Y.-J., Nesselbush, M., Moding, E. J., Nabet, B., Almanza, D., … Diehn, M. (2021). Investigating gene expression profiles associated with clinical radiation resistance in KEAP1/NFE2L2 wildtype lung cancer. CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Circulating tumor DNA kinetics to identify genomic predictors of rapid response to chemoradiation in non-small cell lung cancer.
Moding, E. J., Liu, Y., Hui, A. B., He, J., Qiao, Y., Xu, T., … Diehn, M. (2021). Circulating tumor DNA kinetics to identify genomic predictors of rapid response to chemoradiation in non-small cell lung cancer. CLINICAL CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
NCCN Guidelines Insights: Palliative Care, Version 2.2021.
Dans, M., Kutner, J. S., Agarwal, R., Baker, J. N., Bauman, J. R., Beck, A. C., … Campbell, M. (2021). NCCN Guidelines Insights: Palliative Care, Version 2.2021. Journal of the National Comprehensive Cancer Network : JNCCN, 19(7), 780–788. -
EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.
Shah, M. P., Aredo, J. V., Padda, S. K., Ramchandran, K. J., Wakelee, H. A., Das, M. S., & Neal, J. W. (2021). EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy. Clinical Lung Cancer. -
Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma.
Waliany, S., Zhu, H., Wakelee, H., Padda, S. K., Das, M., Ramchandran, K., … Neal, J. W. (2021). Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer. -
Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer.
Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., … Diehn, M. (2020). Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer. Nature Cancer, 1(2), 176–183. -
Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer.
Generalova, O., Roy, M., Hall, E., Shah, S. A., Cunanan, K., Fardeen, T., … Ramchandran, K. (2021). Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer. Journal of Patient-Reported Outcomes, 5(1), 91. -
Feasibility Study Integrating Electronic Patient-Reported Outcomes (PROs) and Palliative Care for High-Risk Acute Myeloid Leukemia (AML) Patients
Tan, I., Choi, J. H., Cunanan, K., Fronk, J., Zhang, T., Mannis, G. N., & Ramchandran, K. (2021). Feasibility Study Integrating Electronic Patient-Reported Outcomes (PROs) and Palliative Care for High-Risk Acute Myeloid Leukemia (AML) Patients. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP. -
Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer
Gupta, D., Fardeen, T., Teuteberg, W., Seevaratnam, B., Asuncion, M. K., Alves, N., … Ramchandran, K. (2021). Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Association of treatment type with patient-reported quality of life in cancer distress screening
Roy, M., Rosenthal, S., Shah, M. P., Khaki, A. R., Bozkurt, S., Seto, T., … Ramchandran, K. (2021). Association of treatment type with patient-reported quality of life in cancer distress screening. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Association of telemedicine use with disparities in cancer distress screening for patients with limited English proficiency
Roy, M., Fardeen, T., Cabot, A., Bruzzone, B., Savadamuthu, V., Kasprick, D., … Ramchandran, K. (2021). Association of telemedicine use with disparities in cancer distress screening for patients with limited English proficiency. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Palliative Care Always: Hepatology-Virtual Primary Palliative Care Training for Hepatologists.
DeNofrio, J. C., Verma, M., Kosinski, A. S., Navarro, V., Taddei, T. H., Volk, M. L., … Ramchandran, K. (2021). Palliative Care Always: Hepatology-Virtual Primary Palliative Care Training for Hepatologists. Hepatology Communications. -
Patients' perception of meaning of life and needed support before and after cancer treatment initiation
Roy, M., Rosenthal, S., Shah, M., Khaki, A., Hernandez-Boussard, T., & Ramchandran, K. (2021). Patients' perception of meaning of life and needed support before and after cancer treatment initiation. QUALITY OF LIFE RESEARCH. SPRINGER. -
Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer.
Hellyer, J. A., White, M. N., Gardner, R. M., Cunanan, K., Padda, S. K., Das, M., … Wakelee, H. A. (2021). Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer. Clinical Lung Cancer. -
Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.
White, M. N., Piper-Vallillo, A. J., Gardner, R. M., Cunanan, K., Neal, J. W., Das, M., … Wakelee, H. A. (2021). Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib. Clinical Lung Cancer. -
Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens.
Waliany, S., Wakelee, H., Ramchandran, K., Das, M., Huang, J., Myall, N., … Neal, J. W. (2022). Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens. Clinical Lung Cancer. -
Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?
Katsumoto, T. R., Wilson, K. L., Giri, V. K., Zhu, H., Anand, S., Ramchandran, K. J., … Muppidi, S. (2022). Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity? Immunotherapy Advances, 2(1), ltac012. -
Considerations in the reliability and fairness audits of predictive models for advance care planning
Lu, J., Sattler, A., Wang, S., Khaki, A. R., Callahan, A., Fleming, S., … Shah, N. (2022). Considerations in the reliability and fairness audits of predictive models for advance care planning. Frontiers in Digital Health. -
Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology-ASCO Guideline.
Mao, J. J., Ismaila, N., Bao, T., Barton, D., Ben-Arye, E., Garland, E. L., … Bruera, E. (2022). Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology-ASCO Guideline. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2201357. -
Racial diversity and reporting in United States Food and Drug Administration registration trials for thoracic malignancies from 2006-2020.
Chiang, R. S., Desai, A., Glover, M. J., Hui, G., Ramchandran, K. J., Wakelee, H., … Khaki, A. R. (2022). Racial diversity and reporting in United States Food and Drug Administration registration trials for thoracic malignancies from 2006-2020. Cancer Investigation, 1–6. -
Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer.
Hui, C., Qu, V., Wang, J.-Y. Y., von Eyben, R., Chang, Y.-C. C., Chiang, P.-L. L., … Pollom, E. (2022). Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer. Journal of Neuro-Oncology. -
Patient-reported distress at a cancer center during the COVID-19 pandemic.
Shah, M. P., Rosenthal, S., Roy, M., Khaki, A. R., Hernandez-Boussard, T., & Ramchandran, K. (2022). Patient-reported distress at a cancer center during the COVID-19 pandemic. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer.
Gensheimer, M. F., Gupta, D., Patel, M. I., Fardeen, T., Hildebrand, R., Teuteberg, W., … Ramchandran, K. (2022). Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer. JCO Oncology Practice, OP2200128. -
Feasibility of large scale distress screening at an academic center and associated network sites using an adapted patient-reported outcome instrument and reflexive suicide screening.
Gupta, D. M., Savadamuthu, V., Qin, F. F., Roy, M., Herring, J. B., Robinson, A., … Ramchandran, K. (2022). Feasibility of large scale distress screening at an academic center and associated network sites using an adapted patient-reported outcome instrument and reflexive suicide screening. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Plasma Exchange for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Therapy: Implications for Clinical Care and Clinical Trial Design
Giri, V. K., Yunce, M., Muppidi, S., Ramchandran, K. J., Katsumoto, T. R., & Martin-Kool, B. A. (2022). Plasma Exchange for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Therapy: Implications for Clinical Care and Clinical Trial Design. BLOOD. AMER SOC HEMATOLOGY. -
Local Control of Brain Metastases with Osimertinib Alone in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
Hui, C., Qu, V., Wang, J. Y., Von Eyben, R., Chang, Y. C., Chiang, P. L., … Pollom, E. (2022). Local Control of Brain Metastases with Osimertinib Alone in Patients with EGFR-Mutant Non-Small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
Real-world risk of brain metastases in stage III non-small cell lung cancer in the era of PET and MRI staging.
Alhusaini, S., Lanman, T. A., Ko, R. B., Therkelsen, K. E., Eyben, R. V., Diehn, M., … Nagpal, S. (2023). Real-world risk of brain metastases in stage III non-small cell lung cancer in the era of PET and MRI staging. Frontiers in Oncology, 13, 1139940. -
Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents.
Lau, B., Wu, Y. F., No, H. J., Ko, R. B., Devine, M., Das, M. S., … Vitzthum, L. K. (2023). Pulmonary Hemorrhage in Patients Treated with Thoracic Stereotactic Ablative Radiotherapy and Anti-Angiogenic Agents. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer. -
Patient-reported distress at a cancer center during the COVID-19 pandemic.
Shah, M. P., Rosenthal, S. W., Roy, M., Khaki, A. R., Hernandez-Boussard, T., & Ramchandran, K. (2023). Patient-reported distress at a cancer center during the COVID-19 pandemic. Scientific Reports, 13(1), 9581. -
Study of Patient and Physician Attitudes Toward Automated Prognostic Models for Patients With Metastatic Cancer.
Hildebrand, R. D., Chang, D. T., Ewongwoo, A. N., Ramchandran, K. J., & Gensheimer, M. F. (2023). Study of Patient and Physician Attitudes Toward Automated Prognostic Models for Patients With Metastatic Cancer. JCO Clinical Cancer Informatics, 7, e2300023. -
Adoption of Patient-Generated Health Data in Oncology: A Report From the NCCN EHR Oncology Advisory Group
Stetson, P. D., McCleary, N. J., Osterman, T., Ramchandran, K., Tevaarwerk, A., Wong, T., … Weiss, E. (2022). Adoption of Patient-Generated Health Data in Oncology: A Report From the NCCN EHR Oncology Advisory Group. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 20(13). -
Lessons Learned from a Multi-Site, Team-Based Serious Illness Care Program Implementation at an Academic Medical Center.
Seevaratnam, B., Wang, S., Fong, R., Hui, F., Callahan, A., Chobot, S., … Teuteberg, W. (2023). Lessons Learned from a Multi-Site, Team-Based Serious Illness Care Program Implementation at an Academic Medical Center. Journal of Palliative Medicine. -
Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial.
Hui, C., Brown, E., Wong, S., Das, M., Wakelee, H., Neal, J., … Vitzthum, L. K. (2023). Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial. Clinical Lung Cancer. -
Survivorship in Advanced Lung Cancer: Understanding a New Landscape and Opportunities.
Presley, C. J., Dalal, N., Davenport, A. P., Gounden, A., Ramchandran, K., & Tonorezos, E. (2024). Survivorship in Advanced Lung Cancer: Understanding a New Landscape and Opportunities. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, 44(3), e433298. -
Using Patient-Related Outcomes Data to Inform About a Novel Exercise Program in Oncology Patients.
Sibley, A., Schapira, L., & Ramchandran, K. (2024). Using Patient-Related Outcomes Data to Inform About a Novel Exercise Program in Oncology Patients. Journal of Cancer Education : the Official Journal of the American Association for Cancer Education. -
Automated patient selection and care coaches to increase advance care planning for cancer patients.
Gensheimer, M. F., Teuteberg, W., Patel, M. I., Gupta, D., Noroozi, M., Ling, X., … Ramchandran, K. (2024). Automated patient selection and care coaches to increase advance care planning for cancer patients. Journal of the National Cancer Institute. -
A phase 2 single-arm trial of high-dose precision targeted radiotherapy added to immunotherapy for patients with metastatic non-small cell lung cancer.
Gensheimer, M. F., Kotha, N. V., Vitzthum, L. K., Chin, A. L., Jackson, S., 't Erve, I. van, … Neal, J. W. (2024). A phase 2 single-arm trial of high-dose precision targeted radiotherapy added to immunotherapy for patients with metastatic non-small cell lung cancer. International Journal of Radiation Oncology, Biology, Physics.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- A ProspectiveTrial Using Video Images in Advance Care Planning in Hospitalized Seriously Ill Patients With Advanced Cancer
- Buccal Versus Vaginal Misoprostol for Third Trimester Induction of Labor
- Digital Symptom Tracking, Patient Engagement and Quality of Life in Advanced Cancer
- Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer
- A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges
- Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients
- LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib
- Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
Practice Locations
Thoracic Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CA
Thoracic Cancer Program in Palo Alto
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HerePalliative Care in Palo Alto Palo Alto, CA
Palo Alto, CA
Palliative Care in Palo Alto
900 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(163 reviews)
She is amazing, and helpful. Love her.
She is a very caring person and I feel very comfortable with her.
Absolutely excellent physician.
Dr. Ramchandran and her team are the best!!
Dr. Ramchandran and Dr. Ellis-Caleo were very empathetic, caring and warm. If I lived close to Stanford, I would have chosen them as my doctors. I love them.
an absolutely excellent doctor whose I trust implicity with my care,
I geo confident and trust her. She and her staff are kind considerate and clear.
very helpful to understand things
Nice doctor
She is truly wonderful. Great listener, fount of knowledge, gives very good advice, and is caring.
She listened, provides reassurance and expresses concern. I am Happy to have her as part of my care team.
Dr Ramchandran is always very warm and considerate. I feel that she cares about my well being.
Dr. Ramchandran is very empathetic to my health needs. She's a great doctor!!!
She was thorough, and compassionate as was Judy the PA
She’s a great doctor and I would never go anywhere else
She listened & answered all questions
I appreciate Dr. Ramchandran’s knowledge and ability to communicate my healthcare options to me in ways that I can understand where I am able to make important healthcare decisions.
Spectacular. Could not be better.
She is the best!
Great listener, who does not rush her patients. She thinks about and addresses many aspects of the patient’s health and life to improve the quality of both.
I feel very blessed to have her as my physician.
She and her assistant are very nice and very help
Dr. Ramchandran is an empathetic and knowledgeable doctor. Thank you.
Amazing, Compassionate and Caring
Dr Ramchandran is outstanding and I am VERY grateful she is my doctor.
Dr. Ramchandran and her PA Jay are extremely kind and lovely people. They addressed all of my concerns with knowledge and compassion, and I feel I am in excellent hands under their care.
She is amazing really like her
Superb Doctor.
Dr. Ramchandran is very empathetic and very professional!!!
Dr. Ramchandran is a terrific doctor. She carefully listens to me, understands my concerns and involves me in all decisions regarding my treatment and health. I feel blessed to have her leading me through a difficult diagnosis.
She is a very nice doctor
Dr Ramchandran is a jewel. Her questions and comments tend to guide me into more thoughtful responses. She is very gentle and encouraging.
DR. R and her team are the best!!!
Dr. Ram hand ran is very knowledgeable and kindness. We are lucky to have her.
Dr. Kavitha Ramchandran is extremely thorough. I can’t think of anything.
Good doctor
Dr. Ramchandran is very professional, extremely compassionate!!! Thank you doctor!!!
I have been living with and fighting cancer for almost 2 decades there are no words that can do any justification whatsoever in any shape or form to describe Dr Ramchandrans passion and commitment to her patients and field only way possible would be in hieroglyphs or emojis ðŸ˜‡â ¤ï¸ would have to be and angel and heart I am we are truly blessed to have Dr Ramchandran to be by our side through these very difficult times in our lives thank you to all of the amazing individual who all together make the greatest team and hospital in the world and to set the standard of true care and excellence I’m am for ever grateful I would not be here alive today if it was not for my family my standford family
She is a wonderful doctor!
I am so grateful to have Dr. Ramchandran as part of my care team at Stanford. The telehealth visit is always very through and informative. She is also very kind and caring. I feel encouraged and energized by the visits while dealing with a cancer diagnosis.
She gives good explanations about treatment options and decisions, given the changing facts and circumstances we are having to deal with.
Doctor Ramchandran is a great, professional, empathic doctor. Thank you doctor!!!
Nice doctor
Doctor Ramchandran is very empathetic to my situation, and a great, professional doctor. Thank you doctor!!!
Best doctor ever! Listens and is extremely knowledgeable and helpful! Makes us feel very well cared for.
She is a wonderful doctor.
Dr. Ramchandran is great knowing exactly what I mean to say about my condition. Thank your doctor for your support!!!
She was very good, very thorough!
Dr R is fantastic, I’m lucky to have her as my oncologist
Dr. Ramchandran was very attentive and informative. I liked how she explained everything and was courteous and listened well to my comments and concerns. I also appreciate how well she works with my local oncologists and has become a part of my team of doctors. She inspires confidence in the treatment plan going forward. I am thankful to be her patient.
Dr. Ramchandan and her team were very kind, knowledgeable, and thorough in their explanations of treatment options.
Doctor Ramchandran is a very empathetic, knowledgeable, and professional doctor. She gives me great support on this terrible medical journey I'm on. Thank you doctor Ramchandran!!!
My doctor is continuously supplying information and support that I might need and she has my utmost respect and confidence I love my doctor
Her expertise his already added six years to my life and it seems like she will continue to do so.
She is a great doctor with warm heart and very knowledgeable!
She's great -- what more can I say. Understanding, sees the big picture, works to integrate various disciplines.
Dr. Ramchandran is very empathetic and very helpful doctor. She cares a lot for her patients!
She was extremely helpful and very personable.
Dr. Ramchandran was very caring and pleasant. She covered all the issues in detail and gave me plenty of chances to ask questions and answer all the questions patiently. The video visit is as good as an in-person visit.
I'm so pleased that Stanford offers Palliative Care. Dr Ramchandran is a wonderful addition to my oncology care team! She is always compassionate and caring. And she always has excellent suggestions for improving my quality of life.
How a young professional can exude caring about her patients, I do not know. But, she does. We appreciate her and her medical overview. To a long successful life and career...!
Thank you for your unwavering love, care and support. You have allowed my father over five years of great quality of life due to your knowledge and skillful treatment and attention.
Dr. Ramchandran is very empathetic to my medical needs, thank you doctor! She works closely with all my oncologist team. Thank you all!
She seems very thoughtful and concerned about my wellbeing.
Dr. Kavitha Ramchandran is the best, always has been. I was extremely unsettled emotionally and just seeing and hearing her words calmed me down and cheered me up. Grateful.
Dr.Kavitha Ramchandran is a doctor who exudes wisdom without being syrupy. She made me feel safe talking about treatment choices, the correctness of choices, the newer timing choices while validating much of what was presented. She cared about our family support system, and whether we were worried about finances. The treatable aspects were calmly discussed, embuing confidence we really liked her. Many technical. Areas were covered in such a short time. Thank you, Dr. Kavitha Ramchandran.
We have good communication when the tech part is working well.
She is a very good listener and a compassionate doctor. She does not rush visits and makes sure all issues are thoroughly covered.
Doctor Ramchandran is an excellent, empath doctor who does all her Action Items really quick. Thank you doctor! I'm traveling, and she contacted the other doctor whom I needed an answer, and doctor Ramchandran did it as soon as we finished our video doctor's appointment.
MCM
Kavitha Ramchandran is a gifted practitioner who listens well and responds intelligently and with grace. People with incurable disease can speak openly to such a listener, perhaps even get into touch with feelings and medical preferences of which they were unaware. Empathetic listening is an elixir for people who are always being "told" what they should do. It frees them to speak from their hearts and know that they will be heard. Modern medicine is often "selling" a therapy or treatment that the patient feels uneasy about but might hesitate to say. Some people are hesitant to disappoint, let alone contradict, their doctors.
Dr Ramchandran is very knowledgable, kind and compassionate.
She is so thoughtful and caring as always. Everyone who works with her is the same and can really learn from her since she is the definition of excellence.
Dr Ramchandran is such a pleasure to work with. She is always so helpful, positive and encouraging. I am so pleased that I am able to receive Palliative Care at Stanford.
Dr. Ramchandran shows empathy and professionalism to me all the time. Thank you doctor!
I am so happy to have Dr. Ramchandran as my doctor. I balked at getting palliative care but so glad I did. She is so helpful.
She is the best doctor ever and her auxiliary staff is also amazing!
Dr. Ramchandran did an excellent job, she’s referring me to be back and continue with a new chemotherapy.
I can't say enough wonderful things about Dr. Ramchandran. She's professional and a the same time, incredibly empathetic and I always feel better after talking to her. She provides information and help in as positive light as possible and never minimizes my struggles throughout this journey.
I was referred by Kaiser. All the interactions I have had thus far with everyone at Stanford has been great!
Dr Ramchandran is wonderful. She really helps clarify my thoughts by hearing what I say and offering great advice. She's empathetic, kind, professional, understanding, and just overall wonderful to interact with. I can't say enough good things about her.
Dr. Ramchandran is an extremely empathic doctor which helps me to honestly tell her about both my body pains as well a any emotional pain (loss of my kitti). She's great in making you feel treated with your needs. Thank you doctor!
I am excited to be working with her and her team.
Thank you for caring so much. Your support means everything to us. You are very knowledgeable and have given my father five extra years to live already. We cannot thank you enough.
I am very impressed with all employees I encountered at Stanford. Exemplary institution. Especially was impressed with Dr. Ramchandran and her Fellow
Thank you Dr. Ramchandran for always providing thorough and excellent care! I'm so grateful that Stanford offers Palliative Care and that you are part of my team at Stanford.
Dr. Ramchandran is very valuable to me because she has the plan, along with my other doctors, to help me manage my pain and ailments. She's genuinely a caring doctor. Thank you doctor Ramchandran!
Dr Ramchandran is a caring, warm professional. She balances being a doctor and being a human well. Even when we have difficult conversations, she is empathetic and understanding. I can't recommend her enough.
She was very pleasant to talk to, and answered all questions to my satisfaction
Dr. Kavitha Ramchandran is awesome!!!!!
She's simply the best and I feel so lucky to have her as my oncologist.
I found Dr Ramchandran very caring and patient. I believe she listened and heard my concerns with a warm and professional attitude
A great doctor and a caring human being.
Dr. Ram hand ran is the most compassionate, kind, caring doctor I have ever had. How very lucky I was assigned to her. I’m truly blessed.
She has saved my life more than once, and did it in an almost angelic fashion.
Good listener's
Great doctor, great attending docs and great hospital.
Dr. Ramchandran is very empathetic. She agreed with my theory that anger brought from why I have an umbilical hernia brings mental problems to me.
Very satisfactory visit. All questions were answered
Dr Ramchandran was wonderful. I am lucky to have her as part of my care team.
I am so happy to have Dr Ramchandran on my health care team. She is awesome. She listens and tries to help me more than any other doctor on my team.
She listen to me very patiently and provided some good ideas for me for help.
I very much appreciate Dr. Ramchandra
being part of my care team at Stanford.
Excellent
I have been fighting cancer for almost 15 years since Dr Ramchandran has came into my life I am able to function cause of her and the team I’m for ever grateful
Dr Ramchandran is exceptional and caring
Dr. Ramachandran is very , very kind to approach me and warm to my afflictions. Very professional!
Kavitha is a huge help. She really wants to make sure that I have what I need to thrive. I can’t say enough wonderful things about her.
I very much appreciate the palliative care Dr. Ramachandran offers at Stanford.
Doctor Kavitha Ramchandran is a very professional doctor she really cares about the patient. She is always looking for the best way to help. Doctor Kavitha Ramchandran understand my condition and gives me hope. Thank you Doctor Kavitha Ramchandran.
Dr. Ramchandran was very nice , knowledgeable, helpful and compassionate. My wife & I appreciated the time spent on the video conference with her & her team.
Dr. Kavitha has been vety good with explaining my situation and any alternative treatments.
I've enjoyed being her patient and would recommend her to all my family and friends.
I'm very thankful for having her on my team of doctors at Stanford Hospital. She's kind, informative, patient and shows empathy and tries to understand the patients point of view.
Thank you Dr. Kavitha for being such a Wonderful Doctor and for taking care of me.
Dr. Ramchandran is the best! Knowledgable, kind, professional and cares about my outcome. I'd recommend her in a heartbeat.
She is excellent
She is an amazing doctor and I am grateful to be a patient of hers. I live in Stockton so it is far to go to see her and usually go every three months. It would be nice to check in with her on video calls in between as I just did and hope to do again in the future.
The Doctor Kavitha Ramchandran is an excellent and professional doctor, She always really cares about the patient. She looks for the best way to help me deal with the pain and my well-being. Thank you Doctor Kavitha Ramchandran.
Very caring and understanding..
Top notch! I'm so glad to have started seeing Dr Ramchandran.
Dr. Ramchandran is kind, compassionate, has a sense of humor, and able to build trust and rapport with me and my husband. She is patient, a good listener and explains medical terms, procedures in simple, understandable, conversational language. She explains the risks and benefits of my cancer treatment plan and medications in a clear and direct manner. I hold Dr. Ramchandran in high regard and utmost respect. I would recommend her to others with no reservations.
I have been seeing Dr. Ramchandran for about 2 years. She has helped me get through a very difficult period of treatment with chances of survival at 30 to 40%. I went through many emotional swings including depression, fear/anxiety and insomnia to name a few. Also, I had to make many difficult treatment decisions during this time. Dr. Ramchandran was always there in an informed way that aided me in making the decisions. She always brought calmness, intelligence, compassion, insight and sincere caring to the conversation along with when appropriate a sense of humor. She spoke with me not at me. She made sure I understood what the options and outcomes would be. She followed up on what she said she would do.
Many people think Palliative care is only available or used at end of life. In my case a very astute nurse suggested at the beginning of my treatment that I contact Palliative to help me with my emotional state and to make difficult treatment decisions.
I owe a debt of gratitude to Dr. Ramchandran for providing the support I needed to get through this extremely difficult period in my life and along with the rest of my doctors for the success of my treatment.
Very helpful
Dr Ramchandran is exceptionally good at her job. She is honest, compassionate and very knowledgeable in matters of end of life. She is also extremely knowledgable about treatment options and medications for side effect management. My husband and I feel extremely lucky to have her on our care team!!!!!!!
Thank you for being such a good listener
Thank you
Doctor Kavita Ramchandran She is very professional Doctor and she really cares about the condition and situation of her patients. She is looking for all possible means to help her patients.thank you Doctor Kavitha Ramchandran.
She is an excellent doctor.
Dr. Ramchandran is the BEST doctor. She makes us feel very heard and is very responsive to our needs.
Thank you for listening
Dr. Berry and Dr. Ramchandran are the very best!
I felt heard by Dr. Ramchandran and the team. Solutions were clear and I appreciate that they are there to help me navigate this uncertain road.
Dr Ramchandran is extremely knowledgable both in cancer treatments, side effect management, and other palliative care issues. My husband and I are very happy to have her on our medical team!!
She was very clearly and very nice
Most excellent and caring physician. She helped me to see my way clear my end of life prepara
Dr. Ramchandran provides an empathic understanding of my issues. She is always present and looking for ways to help me. I feel free to talk with her about any subject. I have greatly appreciated Dr. Ramchandran assistance throughout my illness.
I would highly recommend both Dr. Kavitha Ramchandran and Dr. Surbhi Singhal.
Very good.
Dr. Schrarger referred me to Dr. Ramchandran (Oncology). I loved her & her assistant.
So thankful to have my care team.
The best care team ever.
Very happy with everything concerning our visit to Stanford but especially w/the time explanations, and overall information we received without even knowing all the right questions to ask.
Dr. "R." was great - thoughtful, kind open & very genuine. She made the experience so positive, and my family & I truly appreciated her.
This is my third consultation for an ongoing condition. I have been very well taken care of.
Great hospital. "Very good in general."
An excellent experience.
We couldn't be more satisfied with Dr. Ramchandran and Connie Li. They spent over one hour with us and made sure we agreed and understood everything. No MD or NP could have done better!
She is wonderful! She gave excellent care and shared information with my Oncologist at Kaiser in Valley. I think this will be a more hopeful outcome now.
Was told I would get a phone call from her the following week and I never did. I still have not heard back. Not happy I never got any kind of notice.
Great.
We love our new doctor she is great. She took everything we said seriously and showed empathy for us.
Good.
Very excellent doctor!
Wonderful team in every way.
Can't say enough good things about the Cancer Clinic.
Above & beyond - Dr. Ramchandran, had a surgeon nurse come in consult & look @ my infected port wound to assure "me" that it was healing properly "to ease my mind."
Very good.
The doctor & her staff are patient and thorough.
Doctor is very nice, warm & caring.
Dr. Ramchandran is wonderful.
Dr. & staff the best very happy to make our switch to Stanford.
Excellent experience.
It is good experience.
Last visit spent most time w/physicians asst. live in Santa Cruz and come to Stanford to see thoracic oncologist - would rather see her - PA very good but stage IV lung cancer - could use reg. oncologist totally - it's your reputation I come for.
Dr. Ramchandran is a dr. above all drs. She's knowledgeable, caring, and concerned genuinely for me. I'm not just a statistical number to her.
The best experience I have had with a doctor.
View More
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records